ERBB2 and neoplasm: Similarly, GCDFP-15 was not a significant prognostic marker for OS or DFS within the biological tumor types (HR+/HER-, HR+/HER2+, HR-/HER2+, HR-/HER2-) or in Farmer tumor types (HR + (AR+/-), HR-/AR+, HR-/AR-; p < 0.05 for each test, not shown).